ARYA Sciences Acquisition V registered with the SEC to offer 13 million shares at $10 each. The offering does not include warrants.
The SPAC is sponsored by Perceptive Advisors. Management in the filing said ARYA V will work to acquire a business focusing on the healthcare or healthcare related industries.
ARYA Sciences IV priced a $130 million IPO in February and is also focused on the healthcare industry. ARYA III merged with Nautilus Biotechnology earlier this month, creating a combined company with an initial market capitalization of approximately $1.3 billion. ARYA II acquired Cerevel Therapeutics in October.
Jefferies and Goldman Sachs are joint book-running managers for the offering. The underwriters have a 45-day option to purchase up to 1.95 million additional shares to cover over-allotments, if any.
The SPAC is led by Chairman Joseph Edelman, who is founder, CEO and portfolio manager of Perceptive Advisors. CEO Adam Stone is CIO of Perceptive Advisors.
ARYA V intends to apply for a Nasdaq listing under ARYE. Read more.
